Stoke Therapeutics, Inc. (NASDAQ:STOK) Stock Has Consensus Target Price of $44.17 According to Brokerages

Key Points

• Analysts are broadly positive: 10 of 11 covering brokerages rate Stoke Therapeutics a buy, giving it a “Moderate Buy” consensus and an average 12-month price target of $44.17.
• Shares opened at $27.76, below the consensus target; the stock’s 12-month range is $22.05–$40.22.
• Quarterly results were mixed: Stoke reported an EPS loss of $1.08, missing estimates of a $0.93 loss, while revenue of $11.26 million exceeded estimates of $8.21 million.

Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK - Get Free Report) have been given a consensus rating of "Moderate Buy" by the eleven brokerages that are covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation and ten have assigned a buy recommendation to the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $44.17.

A number of equities research analysts have commented on STOK shares. Canaccord Genuity Group reduced their target price on Stoke Therapeutics from $60.00 to $58.00 and set a "buy" rating for the company in a report on Tuesday, August 4th. Guggenheim reiterated a "buy" rating and issued a $60.00 price target on shares of Stoke Therapeutics in a report on Tuesday, August 4th. Weiss Ratings cut shares of Stoke Therapeutics from a "sell (d)" rating to a "sell (d-)" rating in a research note on Wednesday, November 4th. JPMorgan Chase & Co. initiated coverage on shares of Stoke Therapeutics in a report on Friday, August 21st. They set an "overweight" rating and a $40.00 price objective on the stock. Finally, Chardan Capital reissued a "buy" rating and set a $35.00 price objective on shares of Stoke Therapeutics in a report on Tuesday, August 4th.

Stoke Therapeutics Price Performance

Stoke Therapeutics stock opened at $27.76 on Thursday. The business has a 50 day simple moving average of $26.60 and a 200-day simple moving average of $30.78. Stoke Therapeutics has a 12 month low of $22.05 and a 12 month high of $40.22. The stock has a market capitalization of $1.82 billion, a PE ratio of -7.36 and a beta of 1.36.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last issued its quarterly earnings results on Thursday, October 29th. The company reported ($1.08) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.93) by ($0.15). Stoke Therapeutics had a negative return on equity of 67.30% and a negative net margin of 862.07%. The firm had revenue of $11.26 million for the quarter, compared to analyst estimates of $8.21 million. As a group, equities research analysts anticipate that Stoke Therapeutics will post -3.91 EPS for the current year.

Insider Activity

In related news, Director Edward Kaye sold 12,567 shares of the business's stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $32.03, for a total value of $402,521.01. Following the sale, the director directly owned 124,557 shares in the company, valued at $3,989,560.71. The trade was a 9.16% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Barry Ticho sold 1,051 shares of Stoke Therapeutics stock in a transaction dated Thursday, October 1st. The stock was sold at an average price of $26.16, for a total transaction of $27,494.16. Following the transaction, the insider owned 19,059 shares of the company's stock, valued at approximately $498,583.44. The trade was a 5.23% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 27,418 shares of company stock worth $860,914. Company insiders own 9.60% of the company's stock.

Institutional Investors Weigh In On Stoke Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of STOK. Quantbot Technologies LP acquired a new stake in Stoke Therapeutics during the second quarter worth approximately $34,000. KBC Group NV purchased a new position in shares of Stoke Therapeutics in the 1st quarter worth $36,000. Western Wealth Management LLC purchased a new position in shares of Stoke Therapeutics in the 1st quarter worth $55,000. Sterling Capital Management LLC boosted its holdings in Stoke Therapeutics by 849.7% in the third quarter. Sterling Capital Management LLC now owns 1,833 shares of the company's stock valued at $48,000 after acquiring an additional 1,640 shares during the last quarter. Finally, EverSource Wealth Advisors LLC grew its position in Stoke Therapeutics by 195.3% during the first quarter. EverSource Wealth Advisors LLC now owns 1,837 shares of the company's stock valued at $60,000 after acquiring an additional 1,215 shares during the period.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing genetic medicines for severe diseases caused by insufficient protein production. The company uses its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) platform to design antisense oligonucleotides that can increase the expression of specific genes and potentially address the underlying causes of genetic disorders. Stoke's leading product candidate is STK-001, an investigational antisense oligonucleotide being developed for the treatment of Dravet syndrome, a severe genetic epilepsy most commonly associated with mutations in the SCN1A gene.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.